Foresite Capital Management IV, LLC Diversified Active

CIK: 0001704132 · Show all filings

Period: Q1 2022 (← Previous) (Next →)

Filing Date: May 13, 2022

Total Value ($000): $357,448 (100.0% shares, 0.0% debt)

Holdings (9)

— Kinnate Biopharma Inc. 30.5%

Value ($000) $108,903 Shares 9,671,643 Est. Cost $39.78 Unrealized —

— Lyell Immunopharma, Inc. 18.8%

Value ($000) $67,075 Shares 13,282,181 Est. Cost $16.24 Unrealized —

PHVS Pharvaris N.V. 16.5%

Value ($000) $59,155 Shares 3,261,926 Est. Cost $31.46 Unrealized -44.1%

ACRS Aclaris Therapeutics, Inc. 14.0%

Value ($000) $49,979 Shares 2,899,034 Est. Cost $15.18 Unrealized -10.1%

KURA Kura Oncology, Inc. 8.3%

Value ($000) $29,747 Shares 1,849,947 Est. Cost $20.39 Unrealized -29.2%

QSI Quantum-Si Incorporated 5.8%

Value ($000) $20,890 Shares 4,463,619 Est. Cost $10.48 Unrealized -53.5%

NRIX Nurix Therapeutics, Inc. 4.0%

Value ($000) $14,441 Shares 1,030,798 Est. Cost $25.20 Unrealized -29.6%

— Cymabay Therapeutics, Inc. 1.6%

Value ($000) $5,558 Shares 1,787,094 Est. Cost $3.49 Unrealized —

HLTHQ Cue Health Inc. 0.5%

Value ($000) $1,700 Shares 263,578 Est. Cost $11.81 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Kinnate Biopharma Inc.	9,671,643	$108,903	30.5%	$39.78	—	COM	49705R105
—	Lyell Immunopharma, Inc.	13,282,181	$67,075	18.8%	$16.24	—	COM	55083R104
PHVS	Pharvaris N.V.	3,261,926	$59,155	16.5%	$31.46	-44.1%	COM	N69605108
ACRS	Aclaris Therapeutics, Inc.	2,899,034	$49,979	14.0%	$15.18	-10.1%	COM	00461U105
KURA	Kura Oncology, Inc.	1,849,947	$29,747	8.3%	$20.39	-29.2%	COM	50127T109
QSI	Quantum-Si Incorporated	4,463,619	$20,890	5.8%	$10.48	-53.5%	COM CL A	74765K105
NRIX	Nurix Therapeutics, Inc.	1,030,798	$14,441	4.0%	$25.20	-29.6%	COM	67080M103
—	Cymabay Therapeutics, Inc.	1,787,094	$5,558	1.6%	$3.49	—	COM	23257D103
HLTHQ	Cue Health Inc.	263,578	$1,700	0.5%	$11.81	—	COM	229790100